NeuVasQ BiotechnologiesRestoring health of mind
NeuVasQ is developing pharmaceuticals to restore blood-brain barrier function in acute neurological disorders such as stroke, epilepsy and neurodegenerative diseases like Alzheimer’s.
NeuVasQ is based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like stroke and epilepsy.
By precisely targeting the pathways responsible for BBB integrity, NeuVasQ has been able to restore lost functionality to the neurovasculature. This unique and targeted approach has the potential to safely improve patient lives in a wide range of neurological disorders.
Currently in a preclinical discovery phase, NeuVasQ is focusing on a range of neurological and neurodegenerative disorders. The company is also considering various innovative therapeutic modalities, including gene and mRNA therapy.
NeuVasQ Biotechnologies is a spin-off founded in February 2021 by the Université Libre de Bruxelles (ULB) and Prof. Benoit Vanhollebeke, a WELBIO investigator at the Laboratory of Neurovascular Signaling at the ULB Neuroscience Institute (UNI) and Professor in the ULB Department of Molecular Biology.
Newton Biocapital is lead investor in NeuVasQ’s EUR 20 million Series A, comprised of EUR 10 million in public investments from regional and national Belgian funding agencies including SFPI-FPIM, the SRIW Group, Investsud and Sambrinvest with a further EUR 10 million in private investments from Newton as lead investor joined by Theodorus IV and business angels from Flanders and Wallonia.